SCHEMBL4184613

SCHEMBL4184613

CC(c1ccccc1)N1CC2CCC1C2OC(=O)Cc1cccc(C2CCCCCC2)c1O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 3/20 0.35
CHRM4 P08173 3/20 0.35
CHRM5 P08912 3/20 0.35
CHRM1 P11229 3/20 0.35
CHRM3 P20309 3/20 0.35
NAAA Q02083 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
P2RX3 P56373 1/20 0.31
ALDH1A1 P00352 2/20 0.31
HPGD P15428 2/20 0.31
NPC1 O15118 1/20 0.31
TSHR P16473 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CYP3A4 P08684 2/20 0.31
CYP2D6 P10635 2/20 0.31
CYP1A2 P05177 1/20 0.31
KDM4E B2RXH2 2/20 0.31
HSD17B10 Q99714 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4985782 0.83 OPRM1 (0.33) NAAAPTGDR2ALDH1A1HPGDKDM4E
SCHEMBL4977956 0.82 OPRM1 (0.34) NAAAPTGDR2OPRM1OPRK1
SCHEMBL4180019 0.80 POLB (0.33) PTGDR2
SCHEMBL4189075 0.79 SIGMAR1 (0.34) NAAAPTGDR2OPRM1OPRK1
SCHEMBL4184504 0.79 OPRM1 (0.33) NAAAPTGDR2P2RX3OPRM1OPRK1
SCHEMBL4193805 0.78 GRIN2B (0.38) PTGDR2ALDH1A1HPGDKDM4E
SCHEMBL4190993 0.77 GRIN2B (0.39) ALDH1A1
SCHEMBL4885818 0.75 NAAA (0.36) CHRM2CHRM1NAAAPTGDR2P2RX3
SCHEMBL4186784 0.75 NAAA (0.39) NAAAPTGDR2ALDH1A1HPGDCYP2D6
SCHEMBL4176861 0.73 ALDH1A1 (0.38) ALDH1A1NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137623-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-28 US disclosed
EP-1968980-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES, LTD. (IN) 2008-09-17 EP disclosed
WO-2007110782-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137623-A1 MUSCARINIC RECEPTOR ANTAGONISTS CHRM2, CHRM1, CHRM5 CHRM2 1/4885CHRM4 7/4885CHRM5 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.